← All trials
NCT07186621
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 10, 2025
- Primary completion
- Jul 9, 2027
- Completion date
- Nov 30, 2028
- First posted
- Sep 22, 2025
- Last posted
- Sep 22, 2025
- Enrollment
- 286
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- People's Liberation Army of ChinaCollaborator
- Eastern Hepatobiliary Surgery HospitalCollaborator
- Peking UniversityCollaborator
- Southern Medical UniversityCollaborator
- Capital Medical UniversityCollaborator
- Chinese Academy of Medical SciencesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.